StockData

Niki BioSolutions, Inc. (NIKI) company profile

NIKINasdaqMeasuring & Controlling Devices, NECFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 4/30
$1.60+0.10 (+6.67%)

Close on Nov 18, 2026Market cap $13.03MP/E –Yield –

About Niki BioSolutions

Measuring & Controlling Devices, NEC, SIC 3829

Aptorum Group Limited is a clinical-stage biopharmaceutical enterprise focused on researching, developing, and commercializing novel therapeutic drug candidates and healthcare solutions. Its primary development pipeline centers on preclinical and clinical drug assets, including its lead projects ALS-4 and SACT-1, with SACT-1 targeted as a pediatric formulation for neuroblastoma. In addition to pharmaceutical drug candidates, the organization previously engaged in healthcare service operations through an outpatient medical clinic known as Talem Medical, serving individual clinical patients via employed physicians.

The company operates an in-house pharmaceutical development facility situated in the Hong Kong Science and Technology Park. Incorporated in the Cayman Islands, the organization maintains principal executive offices in London, United Kingdom, while conducting the substantial majority of its business and operational undertakings from Hong Kong. Its research, development, and regulatory activities span international jurisdictions, including engagements across the United States, Europe, and the People's Republic of China.

Summary of the business section of Niki BioSolutions's latest annual report, written by StockData.

Company profile

Company

Legal name
Niki BioSolutions, Inc.
Headquarters
Princeton, NJ
Address
116 Village Boulevard, Suite 200 08540
Phone
852 3953 7700
Employees
2, Dec 31, 2025
Industry
Measuring & Controlling Devices, NEC
Incorporated in
E9
Fiscal year ends
December 31
Auditor
Marcum Asia CPAs LLP, Guangzhou, China

Stock & identifiers

Ticker
NIKI
Former tickers
APM until Jul 20, 2026
Exchange
Nasdaq
IPO date
Dec 4, 2018
Shares outstanding
8M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jul 20, 2026; 1-for-10 reverse, Jan 23, 2023
SEC CIK
1734005
CUSIP
653942102
ISIN
US6539421023
FIGI
BBG00LX0JFQ4
Share class FIGI
BBG00LX0JGG3
LEI
984500B8DA8D2D9BFA46
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alidad MireskandariPresident & COO20,000
Thomas John FreeburgChief Financial Officer–
Laura A. PhilipsDirector6,024
Kira SheinermanDirector1,515,293
Justin Che Yuen WuDirector1,832
Douglas Wayne ArnerDirector1,062

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 4, 2018
Offer price
$15.80
Exchange
Nasdaq
First trading day
Dec 18, 2018
First-day close
$14.35-9.2%
Lock-up ends (est.)
Jun 16, 2019

“The initial public offering price is $15.80 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date hereof, we have 2 full-time employees, one of whom is the Chief Executive Officer and the other who is engaged in general and administrative functions and who is located in Asia.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 20, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 22, 2026Name changeName changed from Aptorum Group Ltd to Niki BioSolutions, Inc.
Oct 6, 2025MergerRegistration of securities for a merger or exchange offer (S-4)
Dec 14, 2018ListingRegistration of securities on an exchange (Form 8-A)
Dec 4, 2018IPOInitial public offering priced (424B4 prospectus)

See a number that looks wrong?